Mersana Therapeutics Q2 EPS $(0.47) Beats $(0.50) Estimate, Sales $10.65M Beat $8.45M Estimate
Portfolio Pulse from Benzinga Newsdesk
Mersana Therapeutics reported Q2 earnings per share (EPS) of $(0.47), beating the analyst consensus estimate of $(0.50) by 6%. This is a 14.55% increase over losses from the same period last year. The company also reported quarterly sales of $10.65M, beating the analyst consensus estimate of $8.45M by 26.08%. This is a 148.69% increase over sales from the same period last year.
August 08, 2023 | 12:19 pm
News sentiment analysis
Sort by:
Ascending
POSITIVE IMPACT
Mersana Therapeutics reported better than expected Q2 earnings and sales, which could positively impact its stock price.
Mersana Therapeutics reported better than expected Q2 earnings and sales. This positive financial performance could increase investor confidence and drive the stock price up.
CONFIDENCE 90
IMPORTANCE 80
RELEVANCE 100